AUS
NZ
UK
CA
USA
IND
Highlights
- Mesoblast (MSB) secures FDA approval for RYONCIL®.
- RYONCIL becomes the first mesenchymal stromal cell therapy approved in the US.
- Significant impact anticipated for pediatric graft-versus-host disease treatment.
Mesoblast (ASX:MSB) has achieved a significant milestone with the United States Food and Drug Administration (FDA) granting approval for RYONCIL® (remestemcel-L), marking it as the first mesenchymal stromal cell (MSC) therapy to gain approval in the United States. The approval positions RYONCIL as a groundbreaking treatment for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children aged two months and older.
The announcement has brought positive momentum to Mesoblast, reflecting a notable rise in its share price. The treatment provides a critical lifeline for children suffering from SR-aGvHD, a severe condition that often resists existing therapies.
Pivotal Clinical Trial Success
In a pivotal Phase 3 trial, RYONCIL demonstrated an overall response rate of 70% by Day 28 in children with SR-aGvHD, even among severe cases. Impressively, over 85% of patients completed the treatment without interruptions. These results highlight the therapy's potential to transform the landscape of SR-aGvHD treatment.
The therapy also represents a significant advancement for the thousands of patients undergoing allogeneic bone marrow transplants annually in the US. With approximately half of transplant recipients developing acute graft-versus-host disease, and many showing resistance to first-line steroid treatments, RYONCIL fills a critical void in medical care.
Industry Leaders Speak Out
Dr. Joanne Kurtzberg, a leading transplant physician, emphasized the life-changing impact of RYONCIL. She noted its ability to offer hope to children and families previously facing limited options. Similarly, Mesoblast CEO Dr. Silviu Itescu underscored the company's dedication to advancing therapies for inflammatory diseases and outlined plans to pursue FDA approval for additional late-stage products.
A Remarkable Turnaround
The approval follows a challenging period for Mesoblast (MSB), which previously faced setbacks when the FDA requested additional data on RYONCIL. However, the company’s persistence, including direct presentations to the FDA, successfully addressed concerns and led to the approval.
RYONCIL is expected to be available soon at transplant centers across the US, potentially expanding its applications for inflammatory conditions in both children and adults. The FDA's approval highlights the innovation and resilience behind Mesoblast's success, setting the stage for further advancements in cellular medicine.
